RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
 Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Sep 15, 2017 - 4:49:58 AM
Research Article
Latest Research Channel

subscribe to Latest Research newsletter
Latest Research

   EMAIL   |   PRINT
Allergy vaccine is nothing to sneeze at

Mar 21, 2011 - 4:00:00 AM

From there, the scientists can see which models are going to develop an allergy and which are not, to determine the difference between them.


 
[RxPG] Monash University researchers are working on a vaccine that could completely cure asthma brought on by house dust mite allergies.

If successful, the vaccine would have the potential to cure sufferers in two to three doses.

Allergies to house dust mites is a leading cause of asthma and the respiratory condition affects more than 2 million Australians and costs more than $600 million in health expenditure each year.

Currently, people allergic to house dust mites must continually clean their environments to remove the microscopic creatures from soft furnishings to avoid an allergic attack. Medications can bring relief for some sufferers, but must be taken regularly. Others respond less well to medications.

Professor El Meeusen, who is working with Professor Robyn O'Hehir, both from the Faculty of Medicine, Nursing and Health Services, believes that a vaccine for people with house dust mite allergies will have a range of health and financial benefits for patients and the government.

We are aiming to develop a vaccine that can be completely delivered in two to three doses. That means a person suffering from a house dust mite allergy will be able to breathe easily from their final dose, Professor Meeusen said.

Allergies cost the Australian economy approximately seven billion dollars every year. The potential reduction in cost to the patient and to the government by eradicating a common allergy such as this is immense.

Professor O'Hehir has also made significant gains in developing a vaccine for people with peanut allergies. Currently there is no specific treatment for peanut allergy with avoidance and emergency treatment of anaphylaxis with adrenaline as the only options. Allergen immunotherapy is available for selected patients with house dust mite allergy but typically injections need to be given regularly for three to five years.

This method of immunisation is quite precarious, because modern medicine still isn't entirely sure how it really works, Professor Meeusen said.

The immunisation is administered in small doses. Too much can cause anaphylactic shock. It's a very fine line.

Laboratory testing has shown that a genetic predisposition exists to be allergic to more than one allergen.

We have already found that being allergic to peanuts also represents the likelihood of developing an allergy to house dust mites, Dr Meeusen said.

In humans it is difficult to look at how the very early stages of allergy occur, because you don't get to see the patient until it is well developed in their allergic response. Our testing enables us to look at the very first time that our models are exposed to the allergen.

From there, the scientists can see which models are going to develop an allergy and which are not, to determine the difference between them.

This research involves using the scientist's knowledge of normal vaccines for infectious diseases to better understand how allergy vaccines work in order to develop more effective and safer products.




Advertise in this space for $10 per month. Contact us today.


Related Latest Research News


Subscribe to Latest Research Newsletter

Enter your email address:


 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

Online ACLS Certification

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)